PB contributed to the concept development by posing the initial question regarding the observation that approximately 50% of lung cancer patients whose tumors do not have activating EGFR mutations respond to TKI therapy directed against EGFR while another 50% do not; and provided financial support for the initiation of this project. Here, EGFR is linked to lung cancer.